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Open Forum Infectious Diseases
MAJOR ARTICLE

Impact of Obesity on Acyclovir-Induced Nephrotoxicity
Katie E. Barber, Jamie L. Wagner, and Kayla R. Stover
Department of Pharmacy Practice, University of Mississippi School of Pharmacy, Jackson, Mississippi

Background. Obesity is a major medical issue nationally, with rates continually increasing. In obese patients, minimal data exist
for appropriate dosing of acyclovir to decrease the rates of nephrotoxicity. The purpose of this study was to determine the prevalence
of and risk factors associated with acyclovir-induced nephrotoxicity.
Methods. A retrospective case–control of patients who received intravenous acyclovir for >48 hours at the University of
Mississippi Medical Center over a 4-year period were evaluated to elucidate the prevalence of acyclovir-induced nephrotoxicity.
Additionally, risk factors for the development of nephrotoxicity, including the effect of obesity and dosing strategy, were assessed.
Results. One hundred fifteen patients were included in the study. A total of 24 (21%) patients developed nephrotoxicity after
acyclovir exposure and were in the Risk (9.6%), Injury (4.3%), and Failure (7%) categories, defined by the RIFLE criteria. Neither
acyclovir dosage, fluid status, nor baseline characteristics, other than obesity, varied between those who developed nephrotoxicity
vs those who did not. Independent predictors of nephrotoxicity were obesity (odds ratio [OR], 3.2; 95% confidence interval [CI],
1.19–8.67) and receipt of vancomycin (OR, 4.73; 95% CI, 1.57–14.25). No differences in vancomycin dosing or concentrations were
observed between the patients who developed nephrotoxicity and those who did not.
Conclusions. In this study, nephrotoxicity occurred in 21% of patients receiving acyclovir. Concomitant vancomycin receipt and
obesity led to higher rates of toxicity. Efforts should be made to target obese patients on acyclovir plus vancomycin and discontinue
therapy in patients not warranting antiviral coverage to minimize chances of toxicity.
Keywords. acyclovir; antimicrobial stewardship; HSV; nephrotoxicity.
Obesity is a major medical issue nationally, leading to health
complications, morbidity, and mortality. National rates indicate
that >35% of adults are obese, with states where large portions
of the population have low access to care, including Louisiana,
Mississippi, Alabama, and West Virginia, each reporting even
higher rates [1, 2]. In patients who are obese, clinicians are often
challenged regarding how to properly address medical issues,
especially with medications that require dosing based upon
body weight.
Although some weight-based antimicrobials have
recommendations for use of either actual body weight (ABW)
or ideal body weight (IBW), many of these drugs have little evidence available to guide clinician dosing. With the increasing
rates of obesity and morbid obesity, ABW and IBW are increasingly divergent, prompting many clinicians to perform dosage
calculations based upon an adjusted body weight (AdjBW), a
calculated value that falls between the IBW and ABW.
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Acyclovir, approved in 1982 for the treatment of herpes simplex virus (HSV), is one such drug that is dosed according to
weight [3]. A single study evaluated the pharmacokinetics of
acyclovir in 7 morbidly obese patients and 5 normal-weight
patients and displayed similar pharmacokinetics between
groups [4]. Because obese patients displayed comparable pharmacokinetics as normal-weight persons and given data that
demonstrate increased dosages resulting in higher rates of
nephrotoxicity from 12% to 48% [5–7], the recommendation
for IBW dosing was chosen.
Unfortunately, no data exist regarding the rates of nephrotoxicity between the potential dosing weights or the specific cause
of nephrotoxicity in the adult population (ie, direct toxicity from
acyclovir vs a combination of risk factors). Identification of these
risk factors will aid clinicians in providing an evidence-based
approach to current clinical practice, thus providing a higher
quality of care to all patients receiving acyclovir. The purpose
of this study was to determine the prevalence of and risk factors
for acyclovir-associated nephrotoxicity in an adult population
at the University of Mississippi Medical Center (UMMC).
METHODS
Study Design, Setting, and Patient Population

A retrospective case–control study was conducted at UMMC
among adult (≥18 years old) patients who received intravenous (IV) acyclovir for >48 hours between January 1, 2014, and
December 31, 2014. UMMC is a university-affiliated tertiary
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hospital and referral center with >700 inpatient beds. Patients
were identified through use of clinical decision support software (TheraDoc). Excluded patients were those receiving hemodialysis or other forms of renal replacement therapy before
the receipt of acyclovir and those on vasoactive medications. If a
patient received more than 1 course of IV acyclovir, subsequent
exposures were not included. Included patients were analyzed
to determine the frequency of IV acyclovir–associated nephrotoxicity. The patients were divided into 2 groups: those who developed toxicity (cases) and those who did not (controls).
Study Variables and Definitions

Demographics (patient age, gender, race, weight, and
comorbidities), microbiological data, intensive care unit (ICU)
status, and presence of infectious diseases consultation were collected. Additional data collected included information pertaining
to the primary study end point of nephrotoxicity: weight-based
dose, baseline renal function (obtained the day before acyclovir initiation), renal function while on IV acyclovir therapy,
new-onset renal replacement therapy, and reduction in or discontinuation of acyclovir. Lastly, known risk factors for nephrotoxicity were also collected, including concomitant nephrotoxic
agents (aminoglycosides, vancomycin, angiotensin-converting
enzyme inhibitors, and radiocontrast dye) and hydration status
(concomitant fluids). Obesity was defined per the World Health
Organization as a body mass index (BMI) ≥30. Nephrotoxicity
was defined according to the RIFLE criteria, which were calculated with the highest serum creatinine value during acyclovir
therapy [8]. In the microbiologically evaluable population (those
with punch biopsy–proven or polymerase chain reaction [PCR]–
proven viral infection), therapeutic success was assessed via return to baseline mentation for central nervous system (CNS)
involvement or reduction in size, frequency, or crusting of lesions
for cutaneous infections. Acyclovir dosing was recorded as milligram per kilogram of ABW, AdjBW, and IBW.
Statistical Analyses

Statistical analysis was performed using SPSS software, version
23.0 (IBM). Categorical data were analyzed using the chi-square
or Fisher exact test, and continuous data were analyzed using the
Student t test or Mann-Whitney U test, as appropriate. An alpha
of ≤.05 was deemed statistically significant. Variables that had a
P value <.2 on univariate analysis or that were deemed clinically
relevant by the investigators were evaluated for inclusion in a
multivariable logistic regression model, and adjusted odds ratios
(ORs) with associated confidence intervals (CIs) were calculated.
Clinically relevant was defined as variables with prior documentation of contributing to the development of nephrotoxicity.
RESULTS

A total of 115 patients were enrolled in the study. Patient characteristics are listed in Table 1. The median age (interquartile
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range [IQR]) was 54 (37–64) years, with a predominately female
(52%) population. Among the 115 patients, acyclovir-associated
nephrotoxicity, defined by the RIFLE criteria, was observed in
24 (21%) patients. Among those who developed nephrotoxicity,
there were 11 (9.6%) in the Risk category (serum creatinine
increased 1.5× over baseline), 5 (4.3%) in the Injury category
(serum creatinine increased 2× over baseline), and 8 (7%) in the
Failure category (serum creatinine increased 3× over baseline).
No patients experienced loss of renal function beyond 4 weeks.
In univariate analysis, obesity was the only comorbid condition associated with nephrotoxicity (P = .04). There were
no differences in receipt or type of IV hydration or concomitant nephrotoxic agents, other than receipt of vancomycin.
Although 63 (55%) patients received vancomycin, there were
no differences between the 2 groups on maximum vancomycin
dose (P = .76), frequency of initial trough >20 mg/L (P = .71), or
maximum total daily dosage (P = .52). Furthermore, there were
no differences between groups in trough concentrations for any
troughs obtained throughout vancomycin therapy. Baseline
serum creatinine values were similar between groups, with a
median initial value of 0.75 mg/dL (P = .09). As expected, the
patients who developed nephrotoxicity displayed higher serum
creatinine values, with the peak values observed at a median
(IQR) of day 4.5 (3–7) of acyclovir therapy. Of the patients who
developed nephrotoxicity, 4 (17%) needed renal replacement
therapy. More patients (50% vs 22%) who experienced nephrotoxicity were admitted to the ICU during their hospitalization
compared with control patients (P = .01). These patients also
had longer stays in the ICU, at a median (IQR) of 10.5 (7–14.8)
days vs 5 (3–7.5) days, respectively (P = .01). Although total
length of stay was comparable between both groups, the length
of stay postinitiation of acyclovir therapy was 4 days longer in
the patients who developed nephrotoxicity (P = .03).
All patients were initiated on thrice-daily dosing of acyclovir.
The median total daily dose (IQR) was 1950 (1575–2325) mg,
with a median dose of 10.1 (9.9–11.4) mg/kg and 8.1 (6.0–10.2)
mg/kg based upon IBW and ABW, respectively. There were no
differences observed between either group (P = .67). Acyclovirassociated nephrotoxicity was not associated with dosing weight
utilized (P > .05). Patients who developed nephrotoxicity were
treated with acyclovir for a median (IQR) of 8.5 (5.25–11) days,
whereas the control group was treated with acyclovir for a median of 6 (5–9) days (P = .053).
The majority (62%) of patients initiated on acyclovir therapy
had an indication for treatment of a CNS infection. However,
only 17 (15%) patients had positive microbiological results,
with the most commonly identified organism being HSV. There
were no differences between groups in indication for acyclovir,
infection site, time to baseline mentation, or time to lesion size
reduction and lesion crusting.
The majority (80.9%) of patients were on additional agents
known to cause nephrotoxicity, with the most frequently

Table 1.

Patient Demographics
Total Population (n = 115)

Toxicity Group (n = 24)

Nontoxicity Group (n = 91)

P Value

Age, y

54 [37–64]

55 [45–66]

52 [35–64]

.39

Male

55 (47.8)

9 (37.5)

45 (50.5)

.26

Obese

55 (47.8)

16 (66.7)

38 (42.9)

.04

Diabetes

35 (30.4)

6 (25)

29 (31.9)

.52

Dyslipidemia

15 (13)

5 (20.8)

10 (11)

.30

Hypertension

62 (53.9)

16 (66.7)

46 (50.5)

.35

Heart failure

8 (7)

3 (12.5)

5 (5.5)

.36

Chronic kidney disease

12 (10.4)

3 (12.5)

9 (9.9)

.71

Cancer

64 (55.7)

11 (45.58)

53 (58.2)

.28

1 (0.9)

0 (0)

1 (1.1)

1.00

17 (14.8)

6 (25)

11 (12.1)

.19

1 (0.9)

0 (0)

1 (1.1)

1.00
1.00

Comorbid conditions

Renal transplant
Concomitant nephrotoxic agents
ACE inhibitors
Aminoglycosides
Amphotericin

4 (3.5)

1 (4.3)

3 (3.3)

Contrast dye

27 (23.5)

8 (33.3)

19 (20.9)

.20

23 (20)

6 (25)

17 (18.7)

.57

Loop diuretics
NSAIDs

11 (9.6)

2 (8.3)

9 (9.9)

1.00

Vancomycin

63 (54.8)

19 (79.2)

44 (48.4)

.04

Concomitant fluids

94 (81.7)

21 (87.5)

73 (80.2)

.56

Baseline serum creatinine, mg/dL

0.73 [0.6–1.1]

0.6 [0.5–0.8]

0.8 [0.6–1.1]

.07

Highest serum creatinine, mg/dL

0.98 [0.7–1.3]

1.9 [1.1–3]

0.9 [0.7–1.2]

<.001

4 [2–5]

4.5 [3–7]

3 [1–5]

.003

79.5 [67–98]

89.9 [67–120]

79.1 [67–95]

.18

Day of highest serum creatinine, mg/dL
Admission weight, kg
Data are presented as No. (%) or median [interquartile range].

Abbreviations: ACE, angiotensin-converting enzyme; NSAID, nonsteroidal anti-inflammatory drug.

identified concomitant nephrotoxin being vancomycin.
Although more patients in the nephrotoxicity group received
vancomycin, there were no differences in maximum cumulative daily dosage, maximum total dosage, frequency of dosing,
or initial trough values. In multivariate logistic regression, both
obesity (OR, 2.67; 95% CI, 1.04–6.86) and receipt of vancomycin (OR, 4.06; 95% CI, 1.40–11.80) were independently associated with increased nephrotoxicity (Table 2).
CONCLUSIONS

Approximately one-fifth of the patients included developed
acyclovir-associated nephrotoxicity after approximately 5 days
of therapy. Although obesity was the only comorbidity difference between the cases and controls, the total daily acyclovir
dosage did not differ between the 2 groups. Although many
patients received concomitant nephrotoxins, there was an
Table 2. Multivariate Analysis for Independent Risk Factors for AcyclovirAssociated Nephrotoxicity
No. (% Total
Population)

Unadjusted OR
(95% CI)

Obesity

55 (47.8)

2.667 (1.037–6.859)

3.212 (1.191–8.666)

Vancomycin

63 (54.8)

4.059 (1.396–11.804)

4.735 (1.573–14.253)

Abbreviations: CI, confidence interval; OR, odds ratio.

Adjusted OR
(95% CI)

equivalent distribution other than the receipt of vancomycin.
However, patients in both groups had comparable vancomycin
dosing and trough concentrations. Both vancomycin receipt
and obesity were independent risk factors for the development
for acyclovir-associated nephrotoxicity, leading to numerically
increased length of hospital stay and statistically increased
length of stay after acyclovir initiation.
Published rates of acyclovir-associated nephrotoxicity range
between 12% and 48% [5, 9, 10]. However, the effect of obesity
has not been definitively defined, though several case reports
have suggested that weight may be the culprit [11, 12]. Our
study demonstrated comparable findings with a 21% rate of
nephrotoxicity. Additionally, obesity was an independent predictor of nephrotoxicity in these patients. Unfortunately, there
currently is not a consensus on how acyclovir should be dosed
in these patients. An abstract presented at the Interscience
Conference on Antimicrobial Agents and Chemotherapy in
1991 suggested that morbidly obese patients should be dosed according to IBW based upon excessive acyclovir concentrations
in 7 morbidly obese vs 5 normal-weight patients utilizing ABW
[4]. Conversely, Turner and colleagues evaluated IBW dosing
of acyclovir in 14 patients, 7 of whom were morbidly obese,
and determined that systemic exposure in the morbidly obese
patients provided substantially lower exposure than that of the
nonobese patients [13]. Although obesity was a risk factor for
Acyclovir-Induced Nephrotoxicity • ofid • 3

toxicity in our study, we did not observe a difference in the
rates of acyclovir-associated nephrotoxicity regardless of weight
utilized for dosing calculations.
Our study suggests that, in institutions that frequently utilize IV acyclovir, antimicrobial stewardship should target obese
patients on concomitant vancomycin. Only 15% of our patients
yielded positive microbiological results, suggesting that acyclovir exposure could have been minimized in this population and that stewardship efforts should be focused on these
patients. With HSV PCR results available within 24 hours at
many institutions, boasting a sensitivity of up to 90%, acyclovir
therapy should be discontinued as long as clinical judgment
does not warrant continuation [14]. On January 1, 2017, the
Joint Commission released standards recommending antibiotic
timeout at 48 hours as part of a targeted antimicrobial stewardship effort [15]. With nephrotoxicity not occurring until an
average of 4.5 days after acyclovir initiation, it would be prudent to also assess antiviral agents at that time, particularly in
patients receiving concomitant vancomycin.
Although our findings provide more insight into the risk
factors for acyclovir-associated nephrotoxicity, there are several
limitations. We were unable to find a causative dosing strategy
to help aid clinicians in selection of an optimal dose for clinical use. Additionally, we had a small sample in our microbiologically evaluable population, so we cannot suggest improved
or worsened efficacy based upon dosing strategy. Furthermore,
there were more patients who received vancomycin in the
nephrotoxicity group than in the control group, which makes
it difficult to discern if the vancomycin or the acyclovir or both
were responsible for causing nephrotoxicity. Lastly, although we
attempted to be thorough with our data collection, there may be
another factor associated with acyclovir-associated toxicity that
we did not examine.
Acyclovir-associated nephrotoxicity occurred in 21% of
acyclovir-treated patients and was associated with an increased
infection-related length of hospital stay after toxicity development. Both obesity and concomitant vancomycin usage were
independent factors that increased risk for the development of
acyclovir-associated nephrotoxicity. Antimicrobial stewardship
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efforts should target obese patients on acyclovir plus vancomycin
and discontinue therapy in patients not warranting antiviral coverage to minimize toxicity. Further investigations on nephrotoxicity in patients on both vancomycin and acyclovir are warranted.
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